Ptc Therapeutics, Inc. (PTCT) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Ptc Therapeutics’s revenue went from $83M in fiscal 2016 to $1.7B in fiscal 2025, growth of about 40.2% a year.
Net income in fiscal 2025 was $683M, a net margin of 39.4%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $1.2B and net income -$106M.
Free cash flow was $702M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 159% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.7B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M |
| Gross profit | — | — | — | — | — | — | — | $295M | $252M | $190M | $83M |
| Operating income | $148M | $867M | -$303M | -$440M | -$447M | -$374M | -$432M | -$241M | -$116M | -$64M | -$132M |
| Net income | -$106M | $683M | -$363M | -$627M | -$559M | -$524M | -$438M | -$252M | -$128M | -$79M | -$142M |
| EPS (diluted) | $-1.40 | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | $-4.17 |
| R&D | $439M | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M |
| Revenue growth | — | +114.5% | −14.0% | +34.2% | +29.8% | +41.4% | +24.0% | +16.0% | +36.2% | +135.0% | +125.0% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10M | $711M | -$108M | -$158M | -$357M | -$251M | -$194M | -$99M | -$28M | -$10M | -$104M |
| Capital spending | -$8M | -$9M | -$7M | -$28M | -$32M | -$28M | -$18M | -$14M | -$7M | -$3M | -$2M |
| Free cash flow | $2M | $702M | -$114M | -$187M | -$389M | -$280M | -$212M | -$112M | -$35M | -$13M | -$105M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $89M | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.9B | $1.1B | $877M | $411M | $773M | $1.1B | $687M | $228M | $191M | $232M |
| Debt | — | $393M | $371M | $395M | $682M | $512M | $396M | $328M | $164M | $145M | $98M |
| Equity | — | -$205M | -$1.1B | -$819M | -$347M | $1M | $482M | $594M | $351M | $156M | $120M |
| Total assets | — | $2.9B | $1.7B | $1.9B | $1.7B | $1.9B | $2.2B | $1.6B | $1.1B | $392M | $269M |
| Shares (diluted) | 83M | 88M | 77M | 75M | 72M | 70M | 66M | 59M | 47M | 39M | 34M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | 96.0% | 95.2% | 97.7% | 100.0% |
| Operating margin | 12.8% | 50.1% | -37.5% | -46.9% | -64.0% | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% |
| Net margin | -9.2% | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% |
| FCF margin | 0.2% | 40.6% | -14.1% | -19.9% | -55.6% | -51.9% | -55.6% | -36.6% | -13.1% | -6.8% | -127.4% |
| ROIC | — | 453.4% | — | — | -127.1% | -57.6% | -38.9% | -20.7% | -22.5% | -16.9% | -47.9% |
| ROE | — | -332.5% | 33.1% | 76.5% | 161.1% | -36432.6% | -90.9% | -42.3% | -36.5% | -50.5% | -118.8% |
Frequently asked questions
What is Ptc Therapeutics’s annual revenue?
$1.7B in fiscal 2025 and $1.2B over the twelve months to September 30, 2026.
How much profit does Ptc Therapeutics make?
Net income was $683M in fiscal 2025 (net margin 39.4%).
Is Ptc Therapeutics’s revenue growing?
Yes: revenue rose 114.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.